A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells

Front. Immunol.

Sec. T Cell Biology

Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1531294

This article is part of the Research Topic Enhancing T Cell Function: Innovations in Cancer Immunotherapy View all 9 articles

Provisionally accepted

The final, formatted version of the article will be published soon.

You have multiple emails registered with Frontiers:

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Allogeneic chimeric antigen receptor T (CAR-T) therapy, also known as universal CAR-T (UCAR-T) therapy, offers broad applicability, high production efficiency, and reduced costs, enabling quicker access for patients. However, clinical application remains limited by challenges such as immune rejection, and issues with potency and durability. To address these limitations, we developed an 'all-in-one' self-activated and protective (SAP) module, integrated into the CAR scaffold. The SAP module consists of the CD47 extracellular domain, a mutant interleukin 7 receptor alpha (IL7Rα) transmembrane domain, and the IL7Rα intracellular domain, designed to protect UCAR-T cells from host immune attacks and enhance their survival. As anticipated, SAP UCAR-T cells experienced reduced immune rejection from the innate immune system, showed improved persistence and functionality both in vitro and in vivo, and raised no safety concerns. Moreover, the process stability of SAP UCAR-T cells was demonstrated in scale-up production. Overall, our findings highlight the SAP module as a promising strategy for the preclinical development of anti-CD70 UCAR-T, paving the way for an 'off-the-shelf' cell therapy product.

Keywords: chimeric antigen receptor T (CAR-T), allogeneic CAR-T, cancer immunotherapy, Solid tumor, CD70-positive cancer

Received: 20 Nov 2024; Accepted: 30 Dec 2024.

Copyright: © 2024 . This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

留言 (0)

沒有登入
gif